Adamax is described as Semax with an adamantane group attached. The Semax literature is real. A literature for Adamax itself was not found for this note.
Adamax · Modified Semax derivative
Nerve cells rely on signals that support their maintenance and adaptation. Semax, a seven-amino-acid peptide, is studied for its effect on one of those signals, brain-derived neurotrophic factor. Adamax is marketed as a chemically modified Semax. Whether the modification changes what the molecule does is a question no published cell, animal or human study identified here has asked.
Semax is a defined heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro: residues 4 to 7 of adrenocorticotropic hormone (ACTH) followed by Pro-Gly-Pro, a tail added to slow enzymatic breakdown (Dolotov et al., 2006). Adamax is described by its vendors as Semax carrying an adamantane group, typically said to be attached at the N-terminus. Adamantane is a rigid, cage-shaped hydrocarbon that medicinal chemists add to molecules to increase fat solubility and resistance to metabolism; it appears in several approved drugs (Wanka et al., 2013).
That general principle is the entire stated rationale for Adamax. The exact sequence, the point of attachment and the linking chemistry of the material sold under this name were not confirmed for this note, so the structure above is a vendor description, not a verified identity.
For the parent compound, the record is substantial. In rats, intranasal Semax increased brain-derived neurotrophic factor (BDNF) protein in the basal forebrain within hours, and brain membranes from that region showed specific, reversible binding sites for the peptide (Dolotov et al., 2006). Follow-up work mapped changes in BDNF and nerve growth factor gene expression across rat hippocampus, frontal cortex and retina over time (Shadrina et al., 2010). Clinical studies in stroke patients exist in the Russian-language literature and are discussed in the Semax note.
For Adamax, a PubMed search on 22 September 2026 for the compound name and for adamantane-modified Semax returned no relevant results; the only hits were machine-learning papers using an optimiser of the same name. No compound-specific peer-reviewed cell, animal or human study was identified for this note. That does not mean none can exist, particularly outside indexed English-language journals, but none could be found to cite.
Everything specific to the modification. Adding a bulky adamantane group to a short peptide can change whether it binds the same sites, how it is absorbed by any route, and how quickly it is cleared; each of those is an empirical question, and none has a published answer for Adamax. Improved persistence is a design hypothesis, not a demonstrated property. Semax findings, which are themselves mainly animal data plus Russian clinical reports, should not be read across to a derivative whose structure has not been independently confirmed.
No approved medicine containing Adamax was identified in Australia or any other jurisdiction, and no published clinical study of it was found. The parent compound Semax is used clinically in Russia (see note 008); nothing about that use extends to a modified derivative.
Sources and status checked 2026-09-22
Adamax — sizes and pricing